Sutimlimab (Enjaymo)

Sutimlimab is a genuinely different way of interrupting the same complement cascade this site's Berinert, Cinryze, and Conestat Alfa pages all cover — not by replacing the C1 esterase inhibitor those three drugs restore, but by using a monoclonal antibody to block a single downstream enzyme, C1s, outright. It's the first and, as of this review, only FDA-approved treatment for cold agglutinin disease, a rare autoimmune anemia — approved in February 2022 on real Phase 3 evidence, 13 months later than planned after a Complete Response Letter over a third-party manufacturing problem that had nothing to do with the drug's safety or efficacy.

A third point of attack on the same complement pathway

Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia in which cold-reactive IgM autoantibodies bind red blood cells in the cooler peripheral circulation and fix C1, triggering the classical complement pathway — driving both direct intravascular hemolysis and antibody/complement-tagged red-cell destruction in the liver. That's the same classical pathway this site's Berinert and Cinryze and Conestat Alfa pages cover for a different disease, hereditary angioedema — but those three drugs work by replacing or restoring C1 esterase inhibitor (C1-INH), the natural protein that broadly restrains the whole classical pathway (and, separately, the kallikrein-kinin system that drives HAE swelling). Sutimlimab takes a narrower approach: it's a humanized IgG4 monoclonal antibody engineered to bind C1s, the specific serine protease inside the C1 complex that cleaves C4 and C2 to propagate the classical pathway forward. Blocking C1s alone stops the hemolysis-driving step in CAD while leaving C1-INH's other functions, and the separate lectin and alternative complement pathways, intact — a real mechanistic contrast worth knowing if you're comparing complement-targeted drugs on this site rather than assuming they all work the same way.

The molecule was discovered at True North Therapeutics as TNT009 and granted FDA Breakthrough Therapy designation there. Bioverativ acquired True North in June 2017 for a $400 million upfront payment plus up to $425 million in development and sales milestones, gaining worldwide rights and renaming the molecule BIVV009 (later sutimlimab). Sanofi then acquired Bioverativ itself in 2018, making sutimlimab a Sanofi asset for the remainder of its development and its eventual approval.

CARDINAL and CADENZA: the two pivotal trials

Sutimlimab's approval rests on two Phase 3 studies in adults with primary CAD, split by transfusion history. CARDINAL (Röth A, Barcellini W, D'Sa S, et al., "Sutimlimab in Cold Agglutinin Disease," N Engl J Med 2021;384(14):1323-1334, PMID 33625769, DOI 10.1056/NEJMoa2027760) was a 26-week, open-label, single-arm trial in 24 patients with a recent transfusion history; its composite primary endpoint — hemoglobin normalized to at least 12 g/dL, or increased at least 2 g/dL from baseline, without a red-cell transfusion or a prohibited medication — was met by 13 of 24 patients (54%), with 15 of 24 (62.5%) reaching the hemoglobin target alone and 17 of 24 (71%) remaining transfusion-free from week 5 onward. CADENZA (Röth A, et al., "Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial," Blood 2022;140(9):980-991, PMID 35687757, DOI 10.1182/blood.2021014955) was the randomized, placebo-controlled confirmation in 42 patients without a recent transfusion history: the same composite endpoint was met by 16 of 22 (73%) on sutimlimab versus 3 of 20 (15%) on placebo. Between them, the two trials gave FDA both a real single-arm efficacy signal and a genuine placebo-controlled comparison — a more complete evidentiary base than either trial alone, and notably free of the meningococcal infections seen with the C5-targeting complement inhibitors on this site.

A 2020 manufacturing-related rejection, not a clinical one

It's a useful case study alongside this site's other regulatory-delay pages: the CARDINAL data behind the original 2020 submission didn't change between the rejection and the approval, and no new efficacy or safety trial was required in between — the entire 13-month gap was a manufacturing-compliance question at a supplier, resolved without altering the clinical case for the drug.

Real infection risk, but not the meningococcal boxed warning

Enjaymo's label warns that blocking C1s can increase susceptibility to serious infections, including those from encapsulated bacteria such as Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B — serious bacterial or viral infections occurred in 15% (10 of 66) of patients across the CARDINAL and CADENZA trials combined. Patients must be vaccinated against these encapsulated organisms, per current ACIP recommendations, at least two weeks before starting treatment; vaccination reduces but doesn't eliminate the risk. Other labeled warnings cover infusion-related reactions, a risk of new autoimmune disease, and recurrence of hemolysis if sutimlimab is stopped. What the label does not carry is a boxed warning — the strongest FDA label designation — for meningococcal infection, unlike this site's Zilucoplan page and the other C5-targeting complement inhibitors, which do carry that class-wide boxed warning. No meningococcal infections occurred in either pivotal trial, consistent with sutimlimab leaving the terminal complement pathway (C5 and beyond) intact rather than blocking it — a real, mechanism-driven difference, not a marketing distinction.

Current status: the first approved CAD drug, and a stark cost-effectiveness finding

Sanofi markets Enjaymo in the US following its 4 February 2022 approval, with the European Commission granting a parallel EU-wide marketing authorization on 15 November 2022 and a January 2023 US label update adding longer-term safety and efficacy data. It remains the first, and as of this review the only, FDA-approved treatment specifically for cold agglutinin disease. Sanofi set Enjaymo's US list price at roughly $1,800 per vial, with most infusions requiring six to seven vials depending on body weight — an independent cost-effectiveness analysis (Ito S, et al., "Cost-effectiveness of sutimlimab in cold agglutinin disease," Am J Hematol 2024;99(8):1475-1484, PMID 38733355, DOI 10.1002/ajh.27358) put the incremental cost per quality-adjusted life year at roughly $2.34 million against standard supportive care, well above the $150,000 threshold conventionally used in US cost-effectiveness analyses, and estimated that a price cut of more than 80% would be needed to bring it into a conventionally cost-effective range. That's an academic economic finding, not a claim about the drug's clinical benefit, which the CARDINAL and CADENZA data support — but it's a real, published, independent look at what Enjaymo actually costs relative to the health gain it produces, worth knowing alongside the trial results themselves.